Mergers & Acquisitions Mergers & Acquisitions

Comment: Illumina’s EU merger review could move fast now that court has spoken

The EU review of Illumina’s $8 billion takeover of cancer-testing company Grail, on the books since June 2021, could move quickly now that the bloc’s General Court has issued its long-awaited judgment confirming that the European Commission indeed has the right to vet it (see here).

Up until now, waiting fo

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Natalie McNelis

Senior Correspondent

Natalie McNelis covers mergers for MLex in Brussels. Before joining MLex in 2017, she spent 20 years as an international trade and competition lawyer in law firms including Stibbe and WilmerHale. Natalie has a BA in English from Mount Holyoke College, a JD from Harvard Law School and an LLM in EU law from KU Leuven. She is admitted to the bar in New York.

Discover MLex

Stay on top of global regulatory developments

Latest News